Table 4.
The levels of circulating IgG antibodies to BIRC5 and MYC in late stage NSCLC.
| Sample | Patient (n) | Control (n) | t1 | P2 |
|---|---|---|---|---|
| Discovery | ||||
| BIRC5 | 0.87 ± 0.13 (34) | 0.90 ± 0.42 (108) | –0.38 | 0.702 |
| MYC | 0.90 ± 0.34 (34) | 0.72 ± 0.14 (108) | 4.74 | <0.0001 |
| Validation | ||||
| BIRC5 | 0.79 ± 0.21 (39) | 0.77 ± 0.37 (108) | 0.32 | 0.752 |
| MYC | 0.89 ± 0.32 (39) | 0.86 ± 0.16 (108) | 0.80 | 0.423 |
The antibody levels are expressed as mean ± SD in SBI.
1
Student’s t-test (two-tailed).
2
Combining probabilities: X2 = 1.28, df = 4, P = 0.865 for anti-BIRC5 IgG levels and X2 = 26.13, df = 4, P = 0.00003 for anti-MYC IgG levels.